Cardona, Diana M., Claire J. Detweiler, Michael J. Shealy, Anthony D. Sung, Daniel M. Wild, Martin H. Poleski, Bryan L. Balmadrid, Constance T. Cirrincione, David N. Howell, and Keith M. Sullivan. “Use of the National Institutes of Health Consensus Guidelines Improves the Diagnostic Sensitivity of Gastrointestinal Graft-Versus-Host Disease.” Arch Pathol Lab Med 142, no. 9 (September 2018): 1098–1105. https://doi.org/10.5858/arpa.2017-0054-OA.
Sung, Anthony D., Syed Hassan, Diana M. Cardona, Daniel Wild, Krista Rowe Nichols, Hossein Mehdikhani, Bryan Balmadrid, et al. “Late Gastrointestinal Complications of Allogeneic Hematopoietic Stem Cell Transplantation in Adults.” Biol Blood Marrow Transplant 24, no. 4 (April 2018): 734–40. https://doi.org/10.1016/j.bbmt.2017.12.772.
Wild, Daniel, Anthony D. Sung, Diana Cardona, Constance Cirricione, Keith Sullivan, Claire Detweiler, Michael Shealy, et al. “The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.” Dig Dis Sci 61, no. 3 (March 2016): 806–13. https://doi.org/10.1007/s10620-015-3938-8.
Coutré, Steven E., Jacqueline C. Barrientos, Jennifer R. Brown, Sven de Vos, Richard R. Furman, Michael J. Keating, Daniel Li, et al. “Management of adverse events associated with idelalisib treatment: expert panel opinion.” Leuk Lymphoma 56, no. 10 (2015): 2779–86. https://doi.org/10.3109/10428194.2015.1022770.
Shah, Tilak Upendra, Rodger Liddle, M Stanley Branch, Paul Jowell, Jorge Obando, and Martin Poleski. “Pilot study of aprepitant for prevention of post-ERCP pancreatitis in high risk patients: a phase II randomized, double-blind placebo controlled trial.” Jop 13, no. 5 (September 10, 2012): 514–18. https://doi.org/10.6092/1590-8577/855.
Faes, S. K., B. R. Untch, C. Edwards, J. Turner, M. Poleski, and D. S. Tyler. “Management of dieulafoy's lesions,” December 1, 2010, 31–37. https://doi.org/10.1007/978-1-4419-1693-8_4.
Duda, Dan G., Christopher G. Willett, Marek Ancukiewicz, Emmanuelle di Tomaso, Mira Shah, Brian G. Czito, Rex Bentley, et al. “Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer.” Oncologist 15, no. 6 (2010): 577–83. https://doi.org/10.1634/theoncologist.2010-0029.
Willett, Christopher G., Dan G. Duda, Marek Ancukiewicz, Mira Shah, Brian G. Czito, Rex Bentley, Martin Poleski, et al. “A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer.” Oncologist 15, no. 8 (2010): 845–51. https://doi.org/10.1634/theoncologist.2010-0030.
Xu, Lei, Dan G. Duda, Emmanuelle di Tomaso, Marek Ancukiewicz, Daniel C. Chung, Gregory Y. Lauwers, Rekha Samuel, et al. “Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.” Cancer Res 69, no. 20 (October 15, 2009): 7905–10. https://doi.org/10.1158/0008-5472.CAN-09-2099.
Willett, Christopher G., Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Dushyant V. Sahani, Johanna Lahdenranta, et al. “Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study.” J Clin Oncol 27, no. 18 (June 20, 2009): 3020–26. https://doi.org/10.1200/JCO.2008.21.1771.